<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30184038</article-id><article-id pub-id-type="pmc">6122765</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2017-0224</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Quadruple Valve Replacement for Carcinoid Heart
Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mujtaba</surname><given-names>Syed Saleem</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Clark</surname><given-names>Stephen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><aff id="aff1">
<label>1</label> Freeman Hospital Newcastle, United Kingdom of Great Britain and
Northern Ireland.</aff></contrib-group><author-notes><corresp id="c1">Correspondence Address: Syed Saleem Mujtaba, Freeman Hospital
Newcastle upon Tyne NE7 7DN, United Kingdom of Great Britain and Northern
Ireland. E-mail: <email>saleemmujtaba@yahoo.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Jul-Aug</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jul-Aug</season><year>2018</year></pub-date><volume>33</volume><issue>4</issue><fpage>398</fpage><lpage>403</lpage><history><date date-type="received"><day>07</day><month>12</month><year>2017</year></date><date date-type="accepted"><day>26</day><month>2</month><year>2018</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Introduction</title><p>Carcinoid heart disease most frequently involves the tricuspid or, more
rarely, the pulmonary valve and presents with right heart failure as 5-HT is
metabolized by the lung. Left-sided valve involvement is quite rare. We
describe our experience of 3 patients presenting with heart failure
secondary to carcinoid heart disease affecting all four cardiac valves.
There are only four previous isolated case reports in the literature.</p></sec><sec><title>Methods</title><p>All three patients underwent quadruple valve replacement during a single
operation. Right ventricular outflow tract reconstruction with a pericardial
patch was performed in all patients. For 24 hours prior to surgery, all
patients received intravenous octreotide, which continued in intensive care
for at least 24 hours.</p></sec><sec><title>Results</title><p>Mean cross-clamp and bypass times were 175 (range 164-197 minutes) and 210
(range 195-229 minutes) minutes, respectively. Mean intensive treatment unit
(ITU) and inpatient stays were 2.3 (range 2-3 days) and 12 (range 9-16 days)
days, respectively. One patient was reopened for bleeding 4 hours
postoperatively from a ventricular pacing wire site. None required a
permanent pacemaker postoperatively. There were no other complications in
any patient. The quality of life was excellent at 6-16 months clinic
follow-up as they were in NYHA 1. Postoperative echocardiography showed no
paravalvular leaks and well-functioning prostheses in all cases.</p></sec><sec><title>Conclusion</title><p>Surgery to replace all four valves is feasible with excellent medium-term
survival and a very low rate of complications. Patients with carcinoid heart
disease should always be considered for surgery irrespective of the extent
of valvular involvement.</p></sec></abstract><kwd-group><kwd>Carcinoid Heart Disease</kwd><kwd>Malignant Carcinoid Syndrome</kwd><kwd>Heart Valves/surgery</kwd><kwd>Heart Valve Prosthesis Implantation</kwd></kwd-group></article-meta></front><body><table-wrap id="t2" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CT</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Computed tomography</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">NYHA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= New York Heart
Association</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PFO</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Patent foramen
ovale</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Carcinoid heart disease is a rare cause of intrinsic right heart valve disorders,
leading to right heart failure. Left-sided heart valves involvement is occasional.
Cardiac involvement in carcinoid disease generally results in tricuspid
insufficiency and pulmonary stenosis. Carcinoid tumours are neuroendocrine
malignancy. Ninety per cent of all carcinoid tumours are located in the
gastrointestinal system, of which the most common sites are the appendix and
terminal ileum<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>.
Carcinoid tumours must be invasive or metastasise to produce carcinoid syndrome,
which is characterized by facial flushing, diarrhea, and bronchospasm. The incidence
of carcinoid tumours is approximately 1 in 75,000 of the
population<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>, of whom about 50% develop carcinoid syndrome. Once
carcinoid syndrome has developed, approximately 50% of these patients will go on to
develop carcinoid heart disease or Hedinger syndrome.</p></sec><sec sec-type="methods"><title>METHODS</title><p>We describe our experience with 3 patients who underwent simultaneous quadruple valve
replacement for carcinoid heart disease. Patients were in mid 50's (mean 55.3, range
55-56 years, male=1, female=2). All had been diagnosed with a small bowel carcinoid
tumour with liver metastases having initially presented with abdominal pain,
flushing and dyspnoea [New York Heart Association (NYHA) functional class
3-4]. Computed tomography (CT) of the abdomen revealed multiple liver
metastases and a small bowel mesenteric mass. A laparoscopic biopsy was consistent
with a low-grade carcinoid tumor. All had good medium-term estimated prognoses but
were deteriorating rapidly due to congestive heart failure.</p><p>Examination of all patients revealed an elevated jugular venous pressure with
prominent 'V' waves and bilateral pedal oedema. On auscultation, there were systolic
murmurs over the apex and left fourth intercostal space. Early diastolic murmurs
were present at the upper and lower left sternal edges. Echocardiography revealed
advanced features of heart failure. All four cardiac valve leaflets were fixed,
thickened, retracted and failed to coapt. There was at least moderate to severe
regurgitation of all four valves (<xref ref-type="fig" rid="f1">Figures 1</xref> to
<xref ref-type="fig" rid="f3">3</xref>), except in one patient who had mild
tricuspid regurgitation but thickened fixed leaflets consistent with carcinoid
involvement (<xref ref-type="fig" rid="f4">Figures 4</xref> to <xref ref-type="fig" rid="f6">6</xref>). A patent foramen ovale (PFO) was not found in any patient.
The left ventricular function was preserved in two and moderate in the third patient
(mean 50%, range 40-55%), while the right ventricle was dilated with preserved
function. The coronary arteries were disease-free on angiography. Mean logistic
EuroSCORE was 4.1 (range 2.04-7.41).</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Transesophageal echocardiogram showing severe mitral regurgitation.</p></caption><graphic xlink:href="rbccv-33-04-0398-g01"/></fig>
</p><p>
<fig id="f3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Transthoracic echocardiogram showing torrential pulmonary
regurgitation.</p></caption><graphic xlink:href="rbccv-33-04-0398-g03"/></fig>
</p><p>
<fig id="f4" orientation="portrait" position="float"><label>Fig. 4</label><caption><p>Transesophageal echocardiogram showing thickened aortic valve
leaflets.</p></caption><graphic xlink:href="rbccv-33-04-0398-g04"/></fig>
</p><p>
<fig id="f6" orientation="portrait" position="float"><label>Fig. 6</label><caption><p>Transthoracic echocardiogram showing severely thickened tricuspid valve
leaflets.</p></caption><graphic xlink:href="rbccv-33-04-0398-g06"/></fig>
</p><p>Because of the severity of cardiac symptoms, given that there estimated life
expectancy was more than two years and based on the course of their carcinoid
disease, the patients were accepted for surgery.</p><p>An intravenous infusion of octreotide (600 &#x000b5;g in 60 mL 0.9% saline) was
commenced a day before surgery at a rate of 5 mL/h, delivering 50 &#x000b5;g/h
octreotide. This continued during surgery and stopped 48 hours after the operation.
Surgery was performed with the patient on aortobicaval cardiopulmonary bypass via a
midline sternotomy. The patient's systemic temperature was lowered to 32&#x000ba;C,
with myocardial protection being achieved through antegrade cold blood cardioplegia,
which was repeated every 30-45 minutes. All excised valves had a classical
appearance characteristic of carcinoid heart disease (<xref ref-type="fig" rid="f7">Figures 7</xref> and <xref ref-type="fig" rid="f9">9</xref>).</p><p>
<fig id="f7" orientation="portrait" position="float"><label>Fig. 7</label><caption><p>Histology slide of carcinoid aortic valve.</p></caption><graphic xlink:href="rbccv-33-04-0398-g07"/></fig>
</p><p>
<fig id="f9" orientation="portrait" position="float"><label>Fig. 9</label><caption><p>Histology slide of carcinoid pulmonary valve.</p></caption><graphic xlink:href="rbccv-33-04-0398-g09"/></fig>
</p><p>In two patients, the aortic and mitral valves were replaced with CarboMedics
mechanical valves while the tricuspid and pulmonary valves were replaced with
Perimount Magna bioprostheses (<xref ref-type="fig" rid="f10">Figure 10</xref>).
This permitted the use of a postoperative pulmonary artery flotation catheter and
given the durability of bioprostheses in the right heart. In the third patient, all
valves were replaced with Perimount Magna bioprostheses. Right ventricular outflow
tract reconstruction (pulmonary augmentation) with a pericardial patch was performed
in all patients.</p><p>
<fig id="f10" orientation="portrait" position="float"><label>Fig. 10</label><caption><p>Chest X-ray showing all four replaced valves.</p></caption><graphic xlink:href="rbccv-33-04-0398-g10"/></fig>
</p></sec><sec sec-type="results"><title>RESULTS</title><p>The mean cardiopulmonary bypass time was 211 min (range 195-229 min) and the
cross-clamp time 179 min (range 164-197 min). Patients were transferred to the
intensive care unit in a hemodynamically stable condition, with a modest dose of
adrenaline and noradrenaline, and all were extubated on the night of their surgery.
They were temporarily paced for four days with subsequent recovery of their
intrinsic sinus rhythm and the pacing was discontinued. None required a permanent
pacemaker. None had any other postoperative complications what so ever, except for
one patient who required re-exploration 4 hours postoperatively for bleeding from a
right ventricular temporary pacemaker site. All were discharged home in a stable
condition.</p><p>The mean intensive care unit stay was 2 days while the mean hospital stay was 12 days
(range 9-16) (<xref rid="t1" ref-type="table">Table 1</xref>). Postoperative
echocardiography showed all prostheses were seated well with no paravalvular leaks.
All excised valves had pathologic findings consistent with carcinoid heart disease.
They were followed for 6-16 months (mean 12 months) in the outpatient clinic and all
were NYHA class 1. One patient went on to ileal carcinoid tumour and hepatic
metastasis resection.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Outcomes of patients with carcinoid heart disease who underwent quadruple
valve replacement.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Patient</th><th align="center" rowspan="1" colspan="1">1</th><th align="center" rowspan="1" colspan="1">2</th><th align="center" rowspan="1" colspan="1">3</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">56</td><td align="center" rowspan="1" colspan="1">55</td><td align="center" rowspan="1" colspan="1">55</td></tr><tr><td align="left" rowspan="1" colspan="1">Gender</td><td align="center" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">Female</td></tr><tr><td align="left" rowspan="1" colspan="1">NYHA preoperative</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">NYHA postoperative&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Surgery</td><td align="center" rowspan="1" colspan="1">August 2015</td><td align="center" rowspan="1" colspan="1">November 2015</td><td align="center" rowspan="1" colspan="1">August 2016</td></tr><tr><td align="left" rowspan="1" colspan="1">Follow-up (months)</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">PFO</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">X-clamp (minutes)</td><td align="center" rowspan="1" colspan="1">177</td><td align="center" rowspan="1" colspan="1">197</td><td align="center" rowspan="1" colspan="1">164</td></tr><tr><td align="left" rowspan="1" colspan="1">Bypass (minutes)</td><td align="center" rowspan="1" colspan="1">209</td><td align="center" rowspan="1" colspan="1">229</td><td align="center" rowspan="1" colspan="1">195</td></tr><tr><td align="left" rowspan="1" colspan="1">Aortic regurgitation</td><td align="center" rowspan="1" colspan="1">Moderate-severe</td><td align="center" rowspan="1" colspan="1">Moderate-severe</td><td align="center" rowspan="1" colspan="1">Severe</td></tr><tr><td align="left" rowspan="1" colspan="1">Valve implanted</td><td align="center" rowspan="1" colspan="1">23 mm CarboMedics</td><td align="center" rowspan="1" colspan="1">23 mm Perimount Magna</td><td align="center" rowspan="1" colspan="1">19 mm CarboMedics</td></tr><tr><td align="left" rowspan="1" colspan="1">Mitral regurgitation</td><td align="center" rowspan="1" colspan="1">Moderate-severe</td><td align="center" rowspan="1" colspan="1">Severe</td><td align="center" rowspan="1" colspan="1">Severe</td></tr><tr><td align="left" rowspan="1" colspan="1">Valve implanted</td><td align="center" rowspan="1" colspan="1">27 mm CarboMedics</td><td align="center" rowspan="1" colspan="1">25 mm Perimount Magna</td><td align="center" rowspan="1" colspan="1">27 mm CarboMedics</td></tr><tr><td align="left" rowspan="1" colspan="1">Tricuspid regurgitation</td><td align="center" rowspan="1" colspan="1">Severe</td><td align="center" rowspan="1" colspan="1">Severe</td><td align="center" rowspan="1" colspan="1">Mild</td></tr><tr><td align="left" rowspan="1" colspan="1">Valve implanted</td><td align="center" rowspan="1" colspan="1">29 mm Perimount Magna</td><td align="center" rowspan="1" colspan="1">25 mm Perimount Magna</td><td align="center" rowspan="1" colspan="1">25 mm Perimount Magna</td></tr><tr><td align="left" rowspan="1" colspan="1">Pulmonary regurgitation</td><td align="center" rowspan="1" colspan="1">Severe</td><td align="center" rowspan="1" colspan="1">Severe</td><td align="center" rowspan="1" colspan="1">Moderate-severe</td></tr><tr><td align="left" rowspan="1" colspan="1">Valve implanted</td><td align="center" rowspan="1" colspan="1">23 mm Perimount Magna</td><td align="center" rowspan="1" colspan="1">21 mm Perimount Magna</td><td align="center" rowspan="1" colspan="1">23 mm Perimount Magna</td></tr><tr><td align="left" rowspan="1" colspan="1">EuroSCORE</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">Logistic EuroSCORE</td><td align="center" rowspan="1" colspan="1">2.86</td><td align="center" rowspan="1" colspan="1">7.41</td><td align="center" rowspan="1" colspan="1">2.04</td></tr><tr><td align="left" rowspan="1" colspan="1">Left ventricle</td><td align="center" rowspan="1" colspan="1">Good (EF 55%)</td><td align="center" rowspan="1" colspan="1">Moderate (EF 40%)</td><td align="center" rowspan="1" colspan="1">Good (EF 55%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Right ventricle</td><td align="center" rowspan="1" colspan="1">Ventricle dilated</td><td align="center" rowspan="1" colspan="1">Dilated</td><td align="center" rowspan="1" colspan="1">Ventricle dilated</td></tr><tr><td align="left" rowspan="1" colspan="1">ICU stay (days)</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">Hospital stay (days)</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">16</td></tr><tr><td align="left" rowspan="1" colspan="1">Chest drain (mL)</td><td align="center" rowspan="1" colspan="1">2,200</td><td align="center" rowspan="1" colspan="1">250</td><td align="center" rowspan="1" colspan="1">250</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>EF=ejection fraction; ICU=intensive care unit; NYHA=New York Heart
Association; PFO = patent foramen ovale; X-clamp=aortic cross-clamp</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The cardiac manifestations are caused by 5-hydroxytryptamine (5-HT or serotonin)
released by the malignant cells rather than any direct metastatic involvement of the
heart. Preferential right heart involvement is most likely related to inactivation
of the vasoactive substances by the lungs. In 5-10% of cases with left-sided valvar
pathology, one should suspect extensive liver metastases, bronchial carcinoid, or a
patent foramen ovale<sup>[<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r4" ref-type="bibr">4</xref>]</sup>.</p><p>Circulating serotonin levels are more than twofold higher and urine levels of the
serotonin metabolite 5-HIAA are almost fourfold higher in the carcinoid heart
disease patients compared with the noncardiac group. Elevated serum serotonin is
100% sensitive, but only 46% specific for carcinoid heart disease<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>.</p><p>Patients with carcinoid syndrome should be treated in specialized centers by a
multidisciplinary team, including oncologists, cardiologists, pathologists, and
surgeons<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>.
Without intervention, patients may develop progressively worsening symptomatic right
heart failure. Life expectancy is significantly reduced as a result when prognosis
otherwise from the carcinoid tumour may be good in the medium- to long-term. The
Mayo Clinic showed a mean life expectancy of 1.6 years for those with the cardiac
disease compared with 4.6 years for those without cardiac disease in patients with
metastatic midgut carcinoid tumours<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>.</p><p>Medical management is directed by reduction of symptoms caused by right-sided heart
failure and includes fluid and electrolyte management, diuresis, and enhancing
cardiac function. This can be achieved with the use of digoxin, loop and thiazide
diuretics, salt and fluid restrictions, and continuation of somatostatin
analogues<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>.
Treatment with octreotide gives rise to both directly observable clinical benefit
and measurable biochemical improvement. About 70% of patients obtain symptomatic
relief from diarrhea and flushing, showing a decrease in measurable 5-HIAA urinary
secretion and serum 5-HT concentrations<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>. There is some evidence that the use of leucocyte
interferon-alpha controls the secretion of tumour products, can produce a notable
reduction in tumour size with evidence of survival benefit. Unfortunately, however,
there are no data to suggest that either interferon or octreotide can cause any
regression of the cardiac damage caused by carcinoid disease. Cytotoxic chemotherapy
is given for extensive disease and dual endothelin receptor antagonist like bosentan
prevents valvular and mural fibrosis and improve heart function<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>.</p><p>Cardiac surgery offers marked symptomatic improvement of &#x0003e;1 New York Heart
Association class after valve replacement<sup>[<xref rid="r10" ref-type="bibr">10</xref>,<xref rid="r11" ref-type="bibr">11</xref>]</sup>.
There also may be survival benefit with cardiac surgery, although this is difficult
to prove, given the other morbidities in this patient group. The surgical
indications of carcinoid heart disease are symptomatic right ventricular failure,
severe valvular dysfunction and systemic venous pressure elevation<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>. Surgery is
contraindicated in end-stage metastatic disease, patients with poorly controlled
carcinoid symptoms despite octreotide therapy, or hepatic
dearterialization<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>. Median survival after cardiac valve replacement varies
between 6 and 11 years<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>. The improved survival of patients with congestive
cardiac failure in recent years may reflect the increasing surgical expertise in
this field and better perioperative management of the patient with
octreotide<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>.</p><p>More controversial is the choice of the valve prosthesis. Problems for homograft use
for pulmonary valve replacement are homograft constriction, homograft calcification
and homograft plaque deposition. In most cases, the involvement of valve leaflets is
too extensive to allow surgery for commissurotomy or valvotomy, and pulmonary
valvectomy surgery is required<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>. On the one hand, biological prosthetic valve
degeneration with valve allograft failure has been reported to occur as early as 3
months after implantation, being the result of intractable high levels of NET
vasoactive products inducing carcinoid plaque reformation<sup>[<xref rid="r16" ref-type="bibr">16</xref>-<xref rid="r18" ref-type="bibr">18</xref>]</sup>. Evidence for this, however, is relatively weak. On
the other hand, the use of mechanical prosthesis requires life-time anticoagulation
in these patients who have an already increased risk of bleeding due to hepatic
dysfunction. In addition, the risk of mechanical tricuspid mechanical prosthesis
thrombosis is approximately 4% per year<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>. Therefore, choice of the prosthesis should be
tailored to the individual patient risk of bleeding, life expectancy, and future
interventions. An additional consideration is the ability to insert a pulmonary
artery flotation catheter postoperatively through a biological prosthesis to assist
management especially after multivalve replacements in patients with pre-existing
cardiac failure. Although surgical valve replacement is the gold standard treatment
for symptomatic carcinoid heart valve disease, transcatheter pulmonary valve
replacement should be considered as an alternative approach in high-risk
candidates<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>. Percutaneous valve implantation in the pulmonary and
in the inferior vena cava positions may offer minimally invasive alternative in the
high-risk patients<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>.</p><p>Mabvuure et al.<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>
cautiously concluded that biological valves have an acceptable lifespan in patients
with carcinoid syndrome and that the process of valve destruction seen in carcinoid
patients does not continue to a significant level in the bioprosthesis. Although
there opinion lacks, any direct comparative trial or higher-level evidence is
predominantly based on case reports.</p><p>The present article highlights three cases of simultaneous quadruple valve
replacement in for carcinoid heart disease, and further supports the possibility of
not only successful quadruple valve replacement, but also an excellent postoperative
outcome for patients with a reasonable life expectancy and well-controlled disease.
Complications are few and management is aided by perioperative octreotide
infusion.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>Quadruple valve replacement is an acceptable option for patients with a good
prognosis and symptomatic carcinoid heart disease affecting all four heart valves.
An experienced medical, surgical, and anesthetic team approach to the patient with
carcinoid heart disease is critical to provide state-of-the-art management for these
patients. Excellent outcomes can be achieved with low risk of complications.</p><table-wrap id="t3" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">SSM</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SC</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at Freeman Hospital Newcastle, United Kingdom of Great
Britain and Northern Ireland.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>DJ</given-names></name><name><surname>Khattar</surname><given-names>RS</given-names></name></person-group><article-title>Carcinoid heart disease: presentation, diagnosis, and
management</article-title><source>Heart</source><year>2004</year><volume>90</volume><issue>10</issue><fpage>1224</fpage><lpage>1228</lpage><pub-id pub-id-type="pmid">15367531</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bassan</surname><given-names>MD</given-names></name><name><surname>Ahlman</surname><given-names>H</given-names></name><name><surname>Wangberg</surname><given-names>B</given-names></name><name><surname>Modlin</surname><given-names>IM</given-names></name></person-group><article-title>Biology and management of the midgut carcinoid</article-title><source>Am J Surg</source><year>1993</year><volume>165</volume><issue>2</issue><fpage>288</fpage><lpage>297</lpage><pub-id pub-id-type="pmid">8427415</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schweizer</surname><given-names>W</given-names></name><name><surname>Gloor</surname><given-names>F</given-names></name><name><surname>Von Bertrab</surname><given-names>R</given-names></name><name><surname>Dubach</surname><given-names>UC</given-names></name></person-group><article-title>Carcinoid heart disease with left-sided lesions</article-title><source>Circulation</source><year>1964</year><volume>29</volume><fpage>253</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">14119390</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strickman</surname><given-names>NE</given-names></name><name><surname>Rossi</surname><given-names>PA</given-names></name><name><surname>Massumkhani</surname><given-names>GA</given-names></name><name><surname>Hall</surname><given-names>RJ</given-names></name></person-group><article-title>Carcinoid heart disease: a clinical pathologic, and therapeutic
update</article-title><source>Curr Prob Cardiol</source><year>1982</year><volume>6</volume><issue>11</issue><fpage>1</fpage><lpage>42</lpage></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robiolio</surname><given-names>PA</given-names></name><name><surname>Rigolin</surname><given-names>VH</given-names></name><name><surname>Wilson</surname><given-names>JS</given-names></name><name><surname>Harrison</surname><given-names>JK</given-names></name><name><surname>Sanders</surname><given-names>LL</given-names></name><name><surname>Bashore</surname><given-names>TM</given-names></name><etal/></person-group><article-title>Carcinoid heart disease. Correlation of high serotonin levels
with valvular abnormalities detected by cardiac catheterization and
echocardiography</article-title><source>Circulation</source><year>1995</year><volume>92</volume><issue>4</issue><fpage>790</fpage><lpage>795</lpage><pub-id pub-id-type="pmid">7641358</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobson</surname><given-names>R</given-names></name><name><surname>Burgess</surname><given-names>MI</given-names></name><name><surname>Pritchard</surname><given-names>DM</given-names></name><name><surname>Cuthbertson</surname><given-names>DJ</given-names></name></person-group><article-title>The clinical presentation and management of carcinoid heart
disease</article-title><source>Int J Cardiol</source><year>2014</year><volume>173</volume><issue>1</issue><fpage>29</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">24636550</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pellikka</surname><given-names>PA</given-names></name><name><surname>Tajik</surname><given-names>AJ</given-names></name><name><surname>Khandheria</surname><given-names>BK</given-names></name><name><surname>Seward</surname><given-names>JB</given-names></name><name><surname>Callahan</surname><given-names>JA</given-names></name><name><surname>Pitot</surname><given-names>HC</given-names></name><etal/></person-group><article-title>Carcinoid heart disease. Clinical and echocardiographic spectrum
in 74 patients</article-title><source>Circulation</source><year>1993</year><volume>87</volume><issue>4</issue><fpage>1188</fpage><lpage>1196</lpage><pub-id pub-id-type="pmid">7681733</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulke</surname><given-names>MH</given-names></name><name><surname>Mayer</surname><given-names>RJ</given-names></name></person-group><article-title>Carcinoid tumours</article-title><source>N Engl J Med</source><year>1999</year><volume>340</volume><issue>11</issue><fpage>858</fpage><lpage>868</lpage><pub-id pub-id-type="pmid">10080850</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luis</surname><given-names>SA</given-names></name><name><surname>Pellikka</surname><given-names>PA</given-names></name></person-group><article-title>Carcinoid heart disease: diagnosis and management</article-title><source>Best Pract Res Clin Endocrinol Metab</source><year>2016</year><volume>30</volume><issue>1</issue><fpage>149</fpage><lpage>158</lpage><pub-id pub-id-type="pmid">26971851</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Connolly</surname><given-names>HM</given-names></name><name><surname>Schaff</surname><given-names>HV</given-names></name><name><surname>Mullany</surname><given-names>CJ</given-names></name><name><surname>Rubin</surname><given-names>J</given-names></name><name><surname>Abel</surname><given-names>MD</given-names></name><name><surname>Pellikka</surname><given-names>PA</given-names></name></person-group><article-title>Surgical management of left-sided carcinoid heart
disease</article-title><source>Circulation</source><year>2001</year><volume>104</volume><issue>12</issue><supplement>Suppl 1</supplement><fpage>I36</fpage><lpage>I40</lpage><pub-id pub-id-type="pmid">11568027</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Connolly</surname><given-names>HM</given-names></name><name><surname>Nishimura</surname><given-names>RA</given-names></name><name><surname>Smith</surname><given-names>HC</given-names></name><name><surname>Pellikka</surname><given-names>PA</given-names></name><name><surname>Mullany</surname><given-names>CJ</given-names></name><name><surname>Kvols</surname><given-names>LK</given-names></name></person-group><article-title>Outcome of cardiac surgery for carcinoid heart
disease</article-title><source>J Am Coll Cardiol</source><year>1995</year><volume>25</volume><issue>2</issue><fpage>410</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">7829795</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warner</surname><given-names>RRP</given-names></name><name><surname>Castillo</surname><given-names>JG</given-names></name></person-group><article-title>Carcinoid heart disease: the challenge of the unknown
known</article-title><source>J Am Coll Cardiol</source><year>2015</year><volume>66</volume><issue>20</issue><fpage>2197</fpage><lpage>2200</lpage><pub-id pub-id-type="pmid">26564597</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Connolly</surname><given-names>HM</given-names></name><name><surname>Schaff</surname><given-names>HV</given-names></name><name><surname>Abel</surname><given-names>MD</given-names></name><name><surname>Rubin</surname><given-names>J</given-names></name><name><surname>Askew</surname><given-names>JW</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Early and late outcomes of surgical treatment in carcinoid heart
disease</article-title><source>J Am Coll Cardiol</source><year>2015</year><volume>66</volume><issue>20</issue><fpage>2189</fpage><lpage>2196</lpage><pub-id pub-id-type="pmid">26564596</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moller</surname><given-names>JE</given-names></name><name><surname>Pellikka</surname><given-names>PA</given-names></name><name><surname>Bernheim</surname><given-names>AM</given-names></name><name><surname>Schaff</surname><given-names>HV</given-names></name><name><surname>Rubin</surname><given-names>J</given-names></name><name><surname>Connolly</surname><given-names>HM</given-names></name></person-group><article-title>Prognosis of carcinoid heart disease: analysis of 200 cases over
two decades</article-title><source>Circulation</source><year>2005</year><volume>112</volume><issue>21</issue><fpage>3320</fpage><lpage>3327</lpage><pub-id pub-id-type="pmid">16286584</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>SM</given-names></name></person-group><article-title>Valvular disorders in carcinoid heart disease</article-title><source>Braz J Cardiovasc Surg</source><year>2015</year><volume>31</volume><issue>5</issue><fpage>400</fpage><lpage>405</lpage></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Schoen</surname><given-names>FJ</given-names></name></person-group><article-title>Surgical management of carcinoid heart disease</article-title><source>Ann Thorac Surg</source><year>1991</year><volume>52</volume><issue>5</issue><fpage>1208</fpage><lpage>1208</lpage></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Chertow</surname><given-names>GM</given-names></name><name><surname>Karlson</surname><given-names>EW</given-names></name><name><surname>Neish</surname><given-names>AS</given-names></name><name><surname>Schoen</surname><given-names>FJ</given-names></name></person-group><article-title>Bioprosthetic tricuspid valve stenosis associated with extensive
plaque deposition in carcinoid heart disease</article-title><source>Am Heart J</source><year>1991</year><volume>121</volume><issue>6</issue><issue-part>Pt 1</issue-part><fpage>1835</fpage><lpage>1838</lpage><pub-id pub-id-type="pmid">2035407</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohri</surname><given-names>SK</given-names></name><name><surname>Schofield</surname><given-names>JB</given-names></name><name><surname>Hodgson</surname><given-names>H</given-names></name><name><surname>Oakley</surname><given-names>CM</given-names></name><name><surname>Keogh</surname><given-names>BE</given-names></name></person-group><article-title>Carcinoid heart disease: early failure of an allograft valve
replacement</article-title><source>Ann Thorac Surg</source><year>1994</year><volume>58</volume><issue>4</issue><fpage>1161</fpage><lpage>1163</lpage><pub-id pub-id-type="pmid">7944771</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorburn</surname><given-names>CW</given-names></name><name><surname>Morgan</surname><given-names>JJ</given-names></name><name><surname>Shanahan</surname><given-names>MX</given-names></name><name><surname>Chang</surname><given-names>VP</given-names></name></person-group><article-title>Long-term results of tricuspid valve replacement and the problem
of prosthetic valve thrombosis</article-title><source>Am J Cardiol</source><year>1983</year><volume>51</volume><issue>7</issue><fpage>1128</fpage><lpage>1132</lpage><pub-id pub-id-type="pmid">6837458</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heidecker</surname><given-names>B</given-names></name><name><surname>Moore</surname><given-names>P</given-names></name><name><surname>Bergsland</surname><given-names>EK</given-names></name><name><surname>Merrick</surname><given-names>SH</given-names></name><name><surname>Rao</surname><given-names>RK</given-names></name></person-group><article-title>Transcatheter pulmonic valve replacement in carcinoid heart
disease</article-title><source>Eur Heart J Cardiovasc Imaging</source><year>2015</year><volume>16</volume><issue>9</issue><fpage>1046</fpage><lpage>1046</lpage><pub-id pub-id-type="pmid">26003151</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laule</surname><given-names>M</given-names></name><name><surname>Pschowski</surname><given-names>R</given-names></name><name><surname>Pape</surname><given-names>UF</given-names></name><name><surname>Pavel</surname><given-names>M</given-names></name><name><surname>Stangl</surname><given-names>V</given-names></name><name><surname>Baumann</surname><given-names>G</given-names></name><etal/></person-group><article-title>Staged catheter-based valve treatment of severe carcinoid heart
disease</article-title><source>Neuroendocrinology</source><year>2015</year><volume>103</volume><issue>3-4</issue><fpage>259</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">26138598</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mabvuure</surname><given-names>N</given-names></name><name><surname>Cumberworth</surname><given-names>A</given-names></name><name><surname>Hindocha</surname><given-names>S</given-names></name></person-group><article-title>In patients with carcinoid syndrome undergoing valve replacement:
will a biological valve have acceptable durability?</article-title><source>Interact Cardiovasc Thorac Surg</source><year>2012</year><volume>15</volume><issue>3</issue><fpage>467</fpage><lpage>471</lpage><pub-id pub-id-type="pmid">22691379</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Transesophageal echocardiogram showing massive aortic regurgitation.</p></caption><graphic xlink:href="rbccv-33-04-0398-g02"/></fig><fig id="f5" orientation="portrait" position="float"><label>Fig. 5</label><caption><p>Transesophageal echocardiogram showing severely thickened mitral valve
leaflets.</p></caption><graphic xlink:href="rbccv-33-04-0398-g05"/></fig><fig id="f8" orientation="portrait" position="float"><label>Fig. 8</label><caption><p>Histology slide of carcinoid mitral valve.</p></caption><graphic xlink:href="rbccv-33-04-0398-g08"/></fig></floats-group></article>